Genflow Biosciences (LON:GENF) Research Agreement Signed with Magnitude Biosciences Limited

Genflow (LSE: GENF) is pleased to announce it has entered into a research agreement with Magnitude Biosciences Limited (“Magnitude”), a UK-based, specialist biotechnology research organisation that supports drug discovery and product development.

Founded in 2018 as a Durham University spin out, Magnitude provides an automated service to identify health-span extending drugs faster and more cost effectively than current approaches.

Magnitude leverages Artificial Intelligence and uses nematode worms, called C. elegans, for in-vivo testing in aging research, to accelerate early, pre-clinical drug development for biotech and pharmaceutical firms. Its sophisticated ‘Magnitude Biosciences Healthspan technology’ enables it to monitor large numbers of C. elegans under multiple conditions and effectively assess the impact of compounds on health and longevity.

Magnitude is led by Dr Weinkove who has over 20 years’ experience in C. elegans research, deep biological expertise across multiple research areas and a rich track record in the longevity field. Furthermore, he was appointed as the new Chair of the British Society for Research on Ageing in January this year.

The collaboration will accelerate Genflow’s future therapeutic developments and puts the Company on track to carry out its research and pre-clinical drug discovery.

Magnitude will commence generating transgenic strains of C. elegans on behalf of Genflow to test the effect of the expression of human variants of the Sirtuin-6 gene mutation found in centenarians (people aged more than 100 years old) on in-vivo function during aging by analysing C. elegans for age-dependent movement decline.

Genflow is a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with advanced age.

Dr Eric Leire, Founder and CEO of Genflow , said: “We are very excited with this collaboration which gives us the opportunity to work with a company that has tremendous experience in longevity and has a uniquely skilled team. Through this collaboration, Genflow’s future therapeutic developments will be accelerated by Magnitude’s innovative technology which has the capacity to significantly expedite product development, supported by sophisticated machine monitoring.”

For further information please contact:

Genflow Biosciences Plc

Dr Eric Leire

Chief Executive

via Tancredi +44 203 434 2330

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Weekly Newsletter

Sign up to receive exclusive stock market content in your inbox, once a week.

We don’t spam! Read our privacy policy for more info.